• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    3.350 +0.030 (+0.90%)
    Streaming Delayed Price Updated: 12:33 PM EDT, Apr 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,317,291
    Open 3.455
    Bid (Size) 3.350 (7,400)
    Ask (Size) 3.360 (13,700)
    Prev. Close 3.320
    Today's Range 3.310 - 3.500
    52wk Range 1.639 - 5.630
    Shares Outstanding 305,252,194
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
    Via MarketBeat

    Performance

    YTD
    +32.9%
    +32.9%
    1 Month
    -38.1%
    -38.1%
    3 Month
    +31.4%
    +31.4%
    6 Month
    +53.7%
    +53.7%
    1 Year
    +10.6%
    +10.6%

    More News

    Read More
    News headline image
    Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
    Via The Motley Fool
    News headline image
    IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
    Via Stocktwits
    Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
    Via Chartmill
    News headline image
    Iovance Biotherapeutics to Present at Upcoming Conferences
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
    Via Stocktwits
    Topics Earnings
    Curious about the most active stocks on Tuesday? ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Why Did IOVA Stock Gain Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits ↗
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    IOVA Shares Jump 8% — What’s Retail Expecting? ↗
    Via Stocktwits
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗
    Via The Motley Fool
    Topics Death
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
    Via The Motley Fool
    News headline image
    Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings

    Frequently Asked Questions

    Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
    Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
    What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
    The current price of Iovance Biotherapeutics, Inc. - Common Stock is 3.350
    When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 04/08/26 12:33 PM ET
    What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
    The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 1.02B
    How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
    Iovance Biotherapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.